Storia in 2 fonti

Evommune price target lowered to $23 from $28 at Clear Street

Clear Street lowered the firm’s price target on Evommune (EVMN) to $23 from $28 and keeps a Buy rating on the shares. The firm has updated its ...

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

Clear Street lowered the firm’s price target on Evommune (EVMN) to $23 from $28 and keeps a Buy rating on the shares. The firm has updated its ...

Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.